Maravai LifeSciences Holdings, Inc.

a life sciences company

MRVI Nasdaq ISIN US56600D1072 SEC CIK 1823239
Follow Maravai LifeSciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $45.9M +10.1% vs same quarter last year
Net income −$13.8M +45.8% vs same quarter last year
EPS, diluted −$0.09 +50% vs same quarter last year
Operating cash flow $5M +133.1% vs same quarter last year
Revenue by quarter
$56.6M
$46.9M
$47.4M
$41.6M
$49.9M
$65.8M
$51.4M
$45.9M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$500M$0$500M$1BFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$185.7M−$130.8M
FY24$259.2M−$144.8M
FY23$288.9M−$138.4M
FY22$883M$490.7M
FY21$799.2M$469.3M
FY20$284.1M$89M
FY19$143.1M−$4.5M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−150%−100%−50%0%50%100%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2518.3%−115.9%−70.4%
FY2441.8%−90.9%−55.9%
FY2348.5%−11%−47.9%
FY2280.9%65%55.6%
FY2182.4%69.4%58.7%
FY2072%42.2%31.3%
FY1953.3%16.8%−3.1%
Free cash flowOperating cash flow minus capital expenditure
−$200M$0$200M$400M$600MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$70.7M
FY24−$22.2M
FY23$60.7M
FY22$518.9M
FY21$353.7M
FY20$126.8M
FY19$7M
Returned to shareholdersDividends paid and shares bought back
$0$10M$20M$30M$40MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearBuybacks
FY25-
FY24-
FY23-
FY22$0
FY21$0
FY20$33.7M
FY19$0
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Maravai LifeSciences
  • Healthcare median
−100%−50%0%50%100%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearMaravai LifeSciencesHealthcare median
FY25−70.4%−30.6%
FY24−55.9%−47%
FY23−47.9%−58%
FY2255.6%−80.4%
FY2158.7%−71.8%
FY2031.3%−62.2%
FY19−3.1%−46.2%